The AHA and American Society of Health-System Pharmacists today urged the Food and Drug Administration to take appropriate enforcement action to protect patients from a payer-mandated drug distribution model known as “white bagging.” 

Under the white bagging model, commercial health insurers require that patient medications be distributed through a narrow network of specialty pharmacies, often affiliated with the payer. Providers are then required to receive, store and administer the medications without ever taking ownership of the product or having adequate line of sight into the origin or chain of custody of each specific medication it receives, potentially jeopardizing patient safety and limiting the ability of providers to make critical care decisions for their patients. 

“White bagging has surged in frequency over the past decade, creating what amounts to a shadow inventory that hospitals and health systems do not legally own and which exists largely outside of the [Drug Supply Chain Security Act’s] track and trace requirements,” jeopardizing patient safety and exacerbating supply chain security challenges, the organizations said.
 

Perspective
Public
This week, more than 1,000 hospital and health system leaders came to Washington, D.C., united by a shared responsibility: to ensure every community has access…
Headline
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…
Headline
President Trump April 18 signed an executive order to accelerate research into psychedelic drugs for the treatment of serious mental illnesses, calling…
Perspective
Public
Two days from now, the AHA will welcome more than 1,000 health care leaders to our 2026 Annual Membership Meeting in Washington, D.C.This yearly gathering…
Headline
Secretary of Health and Human Services Robert F. Kennedy Jr. April 16 testified during two House hearings on the HHS fiscal year 2027 budget proposal, which…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…